Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH

Infectious disease vaccines

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Nature Reviews Drug Discovery 18, 169-170 (2019)

doi: https://doi.org/10.1038/d41573-018-00011-6

Acknowledgements

We are grateful to D. Thomas, C. Wessel and P. Arthur of the Biotechnology Innovation Organization for their critical review of the data, use of figures and their critical review of this manuscript.

Disclaimer

The opinions expressed in this manuscript are those of the authors and not intended to represent the opinions of the National Vaccine Program Office and the National Vaccine Advisory Committee.

Supplementary Information

  1. 41573_2019_CM16311542_MOESM1_ESM

Competing Interests

M.T.C. is an employee and shareholder of Ology Bioservices, and a board member, consultant and shareholder of NovaDigm Therapeutics. A.K.S. declares no competing interests.

Subjects

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links